https://www.selleckchem.com/products/mbx-8025.html
To analyse the effectiveness of tofacitinib for the treatment of refractory skin thickening in dcSSc. Data from 10 patients with dcSSc treated with tofacitinib (5 mg twice daily) were analysed. A total of 12 dcSSc patients treated with intensive conventional immunosuppressants were selected as the historical comparator group. A clinically relevant response was defined as a decrease in the modified Rodnan skin score (mRSS) of 5 points and ≥25% from baseline. Clinical indicators were compared between the two groups to evaluate the ef